FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| 4DX | $3.66 |
|
$5.42 | $0.23 |
$3.85 |
|
|
| AT1 | $0.04 | 0.00% | $0.05 | $0.01 |
|
||
| AYA | $4.55 |
|
$4.83 | $0.56 |
|
||
| BB1 | $0.99 |
|
$1.11 | $0.31 |
|
||
| BRN | $0.14 |
|
$0.33 | $0.13 |
|
||
| CAT | $3.41 |
|
$7.72 | $2.98 | -33.0 |
$5.856 |
|
| CBL | $0.06 | 0.00% | $0.09 | $0.03 |
|
||
| CGS | $2.16 | 0.00% | $2.97 | $1.15 |
|
||
| CMP | $0.38 |
|
$0.45 | $0.24 |
|
||
| COH | $247.62 |
|
$319.56 | $246.13 | 36.5 |
$299.407 |
|
| CSX | $0.63 |
|
$0.88 | $0.37 |
|
||
| CU6 | $3.09 |
|
$5.87 | $1.43 |
$6.40 |
|
|
| CVB | $0.08 | 0.00% | $0.18 | $0.06 |
$0.15 |
|
|
| CYC | $0.94 |
|
$2.25 | $0.56 |
$1.50 |
|
|
| EBR | $0.80 |
|
$2.08 | $0.70 |
$2.69 |
|
|
| EMV | $1.78 |
|
$2.43 | $1.63 |
$3.15 |
|
|
| EYE | $0.17 | 0.00% | $0.21 | $0.09 |
|
||
| FPH | $33.51 |
|
$35.31 | $29.08 | 48.9 |
$37.00 |
|
| IME | $0.45 | 0.00% | $0.47 | $0.22 |
$0.35 |
|
|
| IMR | $2.00 |
|
$2.25 | $1.12 |
$2.71 |
|
|
| IPD | $0.02 | 0.00% | $0.06 | $0.02 |
$0.088 |
|
|
| LDX | $0.25 |
|
$0.33 | $0.02 |
|
||
| MX1 | $0.09 | 0.00% | $0.12 | $0.04 |
$0.16 |
|
|
| NAN | $3.69 |
|
$5.18 | $3.34 | 55.4 |
$4.55 |
|
| ONE | $0.31 |
|
$0.41 | $0.17 |
$0.50 |
|
|
| PCK | $0.24 | 0.00% | $0.35 | $0.03 |
|
||
| PEB | $0.19 |
|
$0.22 | $0.05 |
|
||
| PGC | $0.20 | 0.00% | $0.56 | $0.20 | 9.5 |
$0.495 |
|
| PME | $133.68 |
|
$336.00 | $155.63 | 92.0 |
$317.717 |
|
| RAP | $0.05 | 0.00% | $0.07 | $0.05 |
|
||
| RMD | $35.89 |
|
$45.25 | $32.04 | 21.1 |
$47.233 |
|
| SHG | $0.22 | 0.00% | $0.42 | $0.18 |
|
||
| SOM | $0.73 |
|
$0.95 | $0.37 | 45.6 |
$0.99 |
|
| TRJ | $0.65 | 0.00% | $1.00 | $0.63 | 24.5 |
$1.175 |
|
3.10% 
Previous Stories
ResMed’s Margin Expansion & Tariff Exemption
Apr 28 2025
ResMed’s largely in-line third quarter results showcased a rising gross margin, while management also moved to ease market concerns regarding tariffs
Trend Remains Up For Catapult International
Feb 18 2025
Michael Gable of Fairmont Equities sees an ongoing uptrend for shares in Catapult Group International
ESG Focus: Top ASX Companies, Superbugs & Hydrogen
Feb 07 2025
Addressing challenges and opportunities in meeting the UN Sustainable Development Goals and what ESG characteristics underpin share prices
ResMed Shakes Off GLP-1 Scare
Feb 04 2025
The great obesity drug scare of 2023 is now behind ResMed as evidence in the December quarter suggests GLP-1s are actually a positive for the sleep apnoea industry
ResMed: Another Positive Quarterly Surprise?
Jan 30 2025
Tomorrow’s release is expected to reveal another strong quarter from ResMed
The Trend Remains Pro Medicus’ Friend
Jan 16 2025
The Chartist reports shares in Pro Medicus are having a breather, with the uptrend likely to continue
Diagnostic Imaging Radiates Opportunity
Dec 18 2024
Pending MRI deregulation is behind the now approved merger of Integral Diagnostics and Capitol Health, and analysts see significant opportunity
ResMed’s Bounce-Back Complete
Oct 29 2024
A stellar first quarter has underscored ResMed’s share price bounce-back from last year’s obesity drug panic, and perhaps put to bed the initial fear of GLP-1s
Dr Boreham’s Crucible: Pro Medicus
Sep 04 2024
The New Criterion’s Tim Boreham explains the ins and outs of one of the undisputed star performers on the ASX
Pro Medicus: Don’t Stop Me Now
Aug 20 2024
Michael Gable of Fairmont Equities reports it doesn’t look like Pro Medicus shares are in a mood to stop rising any time soon
Latest News
| 1 |
FNArena Corporate Results Monitor – 12-02-20262:01 PM - Australia |
| 2 |
Australian Broker Call *Extra* Edition – Feb 12, 20261:26 PM - Daily Market Reports |
| 3 |
The Short Report – 12 Feb 202611:00 AM - Weekly Reports |
| 4 |
A Healthy Correction Underway10:30 AM - International |
| 5 |
AI Fears Overwhelm REA’s Operational Resilience10:00 AM - Australia |